• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    2/15/24 12:31:05 PM ET
    $AGEN
    $AMWL
    $FRES
    $HCTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $AGEN alert in real time by email

    Gainers

    • Sientra (NASDAQ:SIEN) stock rose 193.5% to $0.53 during Thursday's regular session. The market value of their outstanding shares is at $6.3 million.
    • Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 28.78% to $2.55. The market value of their outstanding shares is at $11.0 million.
    • Orgenesis (NASDAQ:ORGS) stock increased by 23.78% to $0.42. The company's market cap stands at $13.4 million.
    • Inspire Veterinary (NASDAQ:IVP) stock rose 23.1% to $0.14. The company's market cap stands at $3.9 million.
    • Inogen (NASDAQ:INGN) stock increased by 20.44% to $10.25. The market value of their outstanding shares is at $238.9 million.
    • American Well (NYSE:AMWL) shares rose 18.91% to $1.32. The company's market cap stands at $379.5 million. The company's, Q4 earnings came out yesterday.

    Losers

    • Renalytix (NASDAQ:RNLX) stock decreased by 32.2% to $0.82 during Thursday's regular session. The market value of their outstanding shares is at $40.9 million. The company's, Q2 earnings came out yesterday.
    • Agenus (NASDAQ:AGEN) stock decreased by 28.88% to $0.66. The company's market cap stands at $251.7 million.
    • Palatin Techs (AMEX:PTN) stock decreased by 21.02% to $3.27. The company's market cap stands at $52.7 million. As per the press release, Q2 earnings came out yesterday.
    • Healthcare Triangle (NASDAQ:HCTI) stock fell 20.73% to $2.83. The company's market cap stands at $12.1 million.
    • Syra Health (NASDAQ:SYRA) shares decreased by 18.06% to $2.27. The market value of their outstanding shares is at $14.5 million.
    • Fresh2 Group (NASDAQ:FRES) shares fell 15.92% to $0.38. The company's market cap stands at $8.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN
    $AMWL
    $FRES
    $HCTI

    CompanyDatePrice TargetRatingAnalyst
    Palatin Technologies Inc.
    $PTN
    12/12/2025$60.00Buy
    Laidlaw
    Palatin Technologies Inc.
    $PTN
    12/3/2025$50.00Buy
    Alliance Global Partners
    Inogen Inc
    $INGN
    6/16/2025$14.00Buy
    B. Riley Securities
    Agenus Inc.
    $AGEN
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    Inogen Inc
    $INGN
    5/22/2025$12.00Hold → Buy
    Needham
    American Well Corporation
    $AMWL
    1/13/2025$15.00Equal Weight → Overweight
    Wells Fargo
    Agenus Inc.
    $AGEN
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    Agenus Inc.
    $AGEN
    7/18/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Palatin Technologies with a new price target

    Alliance Global Partners initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $50.00

    12/3/25 7:47:15 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

    Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform the initiation of its commercial supply of Agenus' lead programs. Th

    3/10/26 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Kevin Smith, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 17, 2026 at 3:00 p.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-p

    3/5/26 9:15:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 5, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that it will report financial results for its fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 12, 2026. The results will be shared in a press release before the market opens.About Syra HealthSyra Health is an integrated healthcare solutions company serving government and commercial healthca

    3/5/26 7:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    $AGEN
    $AMWL
    $FRES
    $HCTI
    SEC Filings

    View All

    SEC Form S-8 filed by American Well Corporation

    S-8 - American Well Corp (0001393584) (Filer)

    3/4/26 5:06:25 PM ET
    $AMWL
    Real Estate

    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    3/3/26 8:11:27 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by American Well Corporation

    144 - American Well Corp (0001393584) (Subject)

    3/2/26 5:23:08 PM ET
    $AMWL
    Real Estate

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Armen Garo H was granted 4,994 shares, increasing direct ownership by 2% to 330,535 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    3/9/26 4:15:05 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Hirschhorn Mark was granted 50,413 shares, increasing direct ownership by 25% to 253,999 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    3/6/26 5:00:35 PM ET
    $AMWL
    Real Estate

    President, International Gotlib Phyllis was granted 50,413 shares, increasing direct ownership by 43% to 166,710 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    3/6/26 4:57:40 PM ET
    $AMWL
    Real Estate

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Leadership Updates

    Live Leadership Updates

    View All

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume

    9/25/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $AMWL
    $FRES
    $HCTI
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook

    Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

    2/24/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Amwell® Announces Results for Fourth Quarter and Full Year 2025

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company's fourth quarter and full year 2025 earnings report can be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/7o2zjx2o/. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a si

    2/12/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate